Research Article
Screening Driving Transcription Factors in the Processing of Gastric Cancer

Guangzhong Xu, Kai Li, Nengwei Zhang, Bin Zhu, and Guosheng Feng

1 Department of General Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
2 Department of General Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

Correspondence should be addressed to Nengwei Zhang; nengwei_zhang@sina.com and Guosheng Feng; guosheng_feng@sina.com

Received 22 December 2015; Revised 18 February 2016; Accepted 16 March 2016

Academic Editor: Niccola Funel

Copyright © 2016 Guangzhong Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Construction of the transcriptional regulatory network can provide additional clues on the regulatory mechanisms and therapeutic applications in gastric cancer. Methods. Gene expression profiles of gastric cancer were downloaded from GEO database for integrated analysis. All of DEGs were analyzed by GO enrichment and KEGG pathway enrichment. Transcription factors were further identified and then a global transcriptional regulatory network was constructed. Results. By integrated analysis of the six eligible datasets (340 cases and 43 controls), a bunch of 2327 DEGs were identified, including 2100 upregulated and 227 downregulated DEGs. Functional enrichment analysis of DEGs showed that digestion was a significantly enriched GO term for biological process. Moreover, there were two important enriched KEGG pathways: cell cycle and homologous recombination. Furthermore, a total of 70 differentially expressed TFs were identified and the transcriptional regulatory network was constructed, which consisted of 566 TF-target interactions. The top ten TFs regulating most downstream target genes were BRCA1, ARID3A, EHF, SOX10, ZNF263, FOXL1, FEV, GATA3, FOXC1, and FOXD1. Most of them were involved in the carcinogenesis of gastric cancer. Conclusion. The transcriptional regulatory network can help researchers to further clarify the underlying regulatory mechanisms of gastric cancer tumorigenesis.

1. Introduction

As one of the most common malignant tumors, gastric cancer is the third cause of cancer-related mortality worldwide, which is mainly related to late presentation. Its incidence is affected by various genetic and environmental factors, reflecting a characteristic geographical distribution. Eastern Asia, Central and Eastern Europe, and South America are higher-risk areas, whereas Northern America and most parts of Africa are low-risk areas [1]. Therefore, it is urgent to uncover the underlying regulatory mechanism of gastric cancer tumorigenesis and identify the useful targets for early diagnosis and treatment.

Many researchers have devoted themselves to study the pathogenesis of gastric cancer and look for the potential targets for diagnosis and treatment. At present, several factors, such as HER2, VEGF, FEGFR, and mammalian target of rapamycin (mTOR), have been considered as targets of therapy for gastric cancer [2]. By bioinformatics method, Jian and Chen suggested that two potentially critical transcription factors, E2F1 and STAT1, may play vital roles in progression of gastric cancer [3]. Recently, the TF-miRNA coregulatory network was constructed, which provided the first evidence to illustrate that altered gene network was associated with gastric cancer invasion [4].

To date, there are still no definitive tools for the diagnosis of gastric carcinoma, due to the fact that regulatory mechanism of gastric cancer is not clarified. The integration of multiple microarray studies may be useful to provide additional evidence for understanding the regulatory mechanism. Herein, we conducted integrated analysis of gastric cancer microarray data and identified more candidate differentially expressed genes (DEGs) between gastric cancer and normal control tissues. Moreover, the significantly enriched functions of these genes were screened and analyzed to discover the biological processes and signaling pathways associated with gastric cancer. A transcriptional regulatory network was further constructed.
2. Materials and Methods

2.1. Microarray Data. Gene Expression Omnibus (GEO) database is a public functional genomics data repository (http://www.ncbi.nlm.nih.gov/geo) [5]. The following key words were used: (“gastric cancer” [MeSH Terms] OR gastric cancer [All Fields]) AND “Homo sapiens” [porgn] AND “gse” [Filter]. The study type was defined as “expression profiling by array.” All the expression profiles were measured using the platform of Affymetrix Human Genome U133 Plus 2.0 Array. All the cancer and normal adjacent gastric tissues were obtained by resection during surgery and immediately frozen in liquid nitrogen.

2.2. Identifying DEGs by Information Theoretic Analysis. Firstly, the six datasets were preprocessed by background correction and normalization. Limma package [6] is the most popular method for the analysis of DEGs, and the gastric cancer and normal samples were compared using Limma package in order to identify the DEGs between the two tissue types. P value was determined by R software using the two-tailed Student’s t-test [7], and the further false discovery rate (FDR) was further calculated. The gene with FDR < 0.01 was considered to indicate a DEG.

2.3. Functional Annotation of DEGs. In order to assess the changes in DEGs occurring at the cellular level and the functional clustering of DEGs, the enrichment analysis tool GeneCodis3 (http://genecodis.cnb.csic.es/analysis/) was used to uncover the biological meaning for groups of genes [8], including Gene Ontology (GO) categories [9] and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation [10].

2.4. Screening the Target Sites of Potential Transcription Factors (TFs). DEGs between gastric cancer and normal tissues could be activated or repressed by TFs. All the TFs in human genome and the motifs of genomic binding sites were downloaded from the TRANSFAC database [11]. Moreover, the position weight matrix (PWM) was also downloaded for gene promoter scanning [12]. The target sites of potential TFs were then identified. Combined with the DEGs obtained from integrated analysis, the differentially expressed targets were screened. Finally, the transcriptional regulatory network was constructed and visualized by Cytoscape software [13].

2.5. Online Validation of Differentially Expressed TFs. The online tool Cancer Browser (https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/) was used to verify the expression of top ten differentially expressed TFs, which regulated the most downstream target genes. We selected the dataset of TCGA stomach adenocarcinoma (STAD) gene expression by RNAseq (Illumina HiSeq), in which 421 samples were enrolled, including 384 cases and 37 normal controls. The dataset ID was TCGA_STAD_exp_HiSeq. We input the names of top ten TFs in the “Genes” item on the top of screen and then clicked the “Go” button and the heat map would appear automatically, which represented the expression level for TFs in different samples.

3. Results

3.1. Identification of DEGs in Gastric Cancer. According to the inclusion criteria, we downloaded six gene expression profiles of gastric cancer from microarray experiments. GEO IDs were GSE13911, GSE19826, GSE34942, GSE35809, GSE51105, and GSE57303. Totally, there were 340 tumor samples and 43 normal gastric tissues, respectively. The types of samples were as follows: GSE13911 (26 intestinal + 6 diffuse + 4 mixed + 2 unclassified), GSE19826 (unknown Lauren subtype), GSE34942 (39 intestinal + 11 diffuse + 6 unclassified), GSE35809 (34 intestinal + 30 diffuse + 6 unclassified), GSE51105 (49 intestinal + 35 diffuse + 10 mixed), and GSE57303 (Lauren subtype not further provided). The characteristics of eligible datasets were summarized in Table 1.

Integrated analysis of six microarray datasets led to 17481 genes. Using the FDR < 0.01 as the statistical significance threshold, a total of 2327 DEGs were identified, including 2100 upregulated DEGs and 227 downregulated DEGs. The top ten upregulated and downregulated DEGs between gastric cancer and normal tissues were listed in Table 2.

3.2. Functional Enrichment Analysis of DEGs. GO enrichment analysis of DEGs was performed to understand their biological functions. In our present study, the three GO categories (biological process, cellular component, and molecular function) were detected, respectively, using web-based software GeneCodis3. The results of enrichment analysis showed that the significantly enriched GO terms for biological process were multicellular organismal process (GO: 32501, FDR = 1.85E−09) and digestion (GO: 7586, FDR = 6.11E−09) (Table 3). Moreover, the extracellular space (GO: 5615, FDR = 4.55E−10) was the significantly enriched GO term for cellular component. Notably, the significantly enriched GO term for molecular functions was extracellular matrix structural constituent (GO: 0005201, FDR = 2.82E−04).

Moreover, the KEGG pathway enrichment analysis indicated that cell cycle (FDR = 4.81E−33) was significantly enriched (Table 4). Furthermore, several pathways were also significantly enriched which may be closely related to transcription and translation process, including spliceosome (FDR = 5.45E−34), RNA transport (FDR = 8.58E−23), ribosome biogenesis in eukaryotes (FDR = 5.29E−22), and homologous recombination (FDR = 3.89E−08).

3.3. Building Up TFs-Target Genes Regulatory Network for Gastric Cancer. In order to display the TFs-target genes regulatory network for gastric cancer, we utilized TRANSFAC to inquire TFs and their latent target genes and then selected the differentially expressed TFs and latent target genes in gastric cancer tissues. We found a total of 70 differentially expressed TFs (54 upregulated and 16 downregulated) and 470 latent differentially expressed target genes in gastric cancer, respectively (Table 5). And, based on them, the transcriptional regulatory network was subsequently constructed. In the network, there were 63 TFs (49 upregulated and 14 downregulated) and 566 TF-target interactions in the context of gastric cancer (Figure 1). No differentially expressed target genes were found for the other seven TFs. In the network,
Table 1: Characteristics of the six microarray datasets for integrated analysis.

| GEO ID   | Platform          | Sample (case: control) | Country | Year | Author               |
|----------|-------------------|-------------------------|---------|------|----------------------|
| GSE13911 | GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array | 38:31 | Italy | 2008 | D’Errico et al. [31] |
| GSE19826 | GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array | 12:12 | China | 2010 | Wang et al. [32]     |
| GSE34942 | GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array | 56:0  | Singapore | 2014 | Lei et al. [33]     |
| GSE51809 | GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array | 70:0  | Singapore | 2014 | Lei et al. [33]     |
| GSE51105 | GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array | 94:0  | Australia | 2014 | Busuttil et al. [34] |
| GSE57303 | GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array | 70:0  | China | 2014 | Qian et al. [35]     |
Table 2: Top ten upregulated and downregulated DEGs between gastric cancer and normal tissues.

| Symbol  | Log FC | P value |
|---------|--------|---------|
| CST1    | 5.02E + 00 | 3.12E – 29 |
| MMP1    | 3.27E + 00 | 5.35E – 24 |
| COL1A1  | 3.27E + 00 | 1.21E – 30 |
| GDF5    | 3.10E + 00 | 5.16E – 29 |
| UBD     | 3.02E + 00 | 8.33E – 18 |
| APOC1   | 3.02E + 00 | 1.03E – 25 |
| SPPI    | 2.92E + 00 | 1.67E – 16 |
| CTHRC1  | 2.85E + 00 | 3.95E – 30 |
| COL10A1 | 2.84E + 00 | 1.95E – 19 |
| INHBA   | 2.80E + 00 | 8.79E – 33 |
| GKN1    | −5.70E + 00 | 6.73E – 17 |
| GKN2    | −4.57E + 00 | 7.42E – 19 |
| PGA3    | −4.45E + 00 | 2.89E – 16 |
| MAL     | −4.19E + 00 | 1.50E – 33 |
| PG5     | −3.73E + 00 | 1.24E – 19 |
| ATP4B   | −3.49E + 00 | 7.36E – 24 |
| GIF     | −3.33E + 00 | 4.22E – 17 |
| ATP4A   | −3.24E + 00 | 2.52E – 24 |
| DPT     | −3.22E + 00 | 1.67E – 32 |
| C2orf40 | −3.17E + 00 | 5.14E – 17 |

In this study, according to integrated analysis of six microarray datasets for gastric cancer, 2327 DEGs were the top ten TFs regulating most downstream target genes were BRCA1, ARID3A, EHF, SOX10, ZNF263, FOXL1, FEV, GATA3, FOXC1, and FOXD1. The three hub TFs were BRCA1 (degree = 49), ARID3A (degree = 47), and EHF (degree = 42).

3.4. Online Validation of Differentially Expressed TFs. The top ten differentially expressed TFs were selected for validation. The online validation revealed that expression patterns of the ten TFs were similar to the integrated analysis. The results revealed that SOX10 and FEV were downregulated, while BRCA1, ARID3A, EHF, ZNF263, FOXL1, GATA3, FOXC1, and FOXD1 were upregulated in primary gastric adenocarcinoma compared with the normal lung tissue (Figure 2).

4. Discussion

Gastric cancer has few symptoms during the early stages, and most patients are usually diagnosed after the cancer has progressed to an advanced stage, which results in short survival times. Therefore, the high mortality rate underlines the need for early diagnosis and effective medical treatments for the patients [14]. The transcriptional regulatory network may be helpful to understand the underlying regulatory mechanisms and provide additional evidence for therapeutic applications.

In this study, according to integrated analysis of six microarray datasets for gastric cancer, 2327 DEGs were
Figure 2: Heat map of top ten differentially expressed TFs in the dataset of TCGA stomach adenocarcinoma (STAD) gene expression by RNAseq. Sample type: green indicates the primary tumor of stomach adenocarcinoma \( (n = 384) \); grey indicates the normal lung tissue \( (n = 37) \). For each gene, red is upregulated and blue is downregulated in the corresponding sample.

Table 3: Enriched GO terms of DEGs between gastric cancer and normal tissues.

| GO ID   | GO term                              | Number of genes | FDR       |
|---------|--------------------------------------|-----------------|-----------|
| 32501   | Multicellular organismal process     | 58              | \(1.85E-09\) |
| 3008    | System process                       | 32              | \(1.96E-09\) |
| 7586    | Digestion                            | 9               | \(6.1E-09\)  |
| 44707   | Single-multicellular organismal process | 56         | \(6.97E-09\) |
| 42391   | Regulation of membrane potential    | 14              | \(1.14E-06\) |
| 44057   | Regulation of system process         | 13              | \(1.23E-06\) |
| 7610    | Behavior                             | 20              | \(1.27E-06\) |
| 43269   | Regulation of ion transport          | 17              | \(1.90E-06\) |
| 9719    | Response to endogenous stimulus     | 30              | \(2.12E-06\) |
| 1903522 | Regulation of blood circulation      | 10              | \(4.21E-06\) |
| 5615    | Extracellular space                  | 22              | \(4.55E-10\) |
| 44459   | Plasma membrane part                 | 48              | \(1.61E-09\) |
| 44421   | Extracellular region part            | 58              | \(6.19E-09\) |
| 5576    | Extracellular region                 | 34              | \(6.60E-09\) |
| 31226   | Intrinsic component of plasma membrane | 33          | \(7.45E-09\) |
| 5887    | Integral component of plasma membrane | 31         | \(4.49E-08\) |
| 31224   | Intrinsic component of membrane      | 72              | \(4.86E-08\) |
| 44425   | Membrane part                        | 85              | \(7.79E-08\) |
| 1990351 | Transporter complex                  | 13              | \(3.66E-07\) |
| 1902495 | Transmembrane transporter complex    | 13              | \(4.00E-07\) |
| 16021   | Integral component of membrane       | 69              | \(4.13E-07\) |
| 97458   | Neuron part                          | 31              | \(4.20E-07\) |
| 34702   | Ion channel complex                  | 11              | \(2.16E-06\) |
| 5886    | Plasma membrane                      | 53              | \(2.64E-06\) |
| 98590   | Plasma membrane region               | 22              | \(3.34E-05\) |
| 0005201 | Extracellular matrix structural constituent | 8          | \(2.82E-04\) |
| 0043168 | Anion binding                        | 164             | \(4.39E-04\) |
strong expression of ARID3A may predict a good prognosis in patients with colorectal carcinoma, and Song et al. mentioned that whether ARID3A acts as an oncogene or tumor suppressor remains controversial [19]. In our study, we found that ARID3A was upregulated in gastric cancer compared with normal tissues. Therefore, we speculated that ARID3A may act as an oncogene in the development of gastric cancer.

Abnormalities of SOX factors have been shown to play critical roles in cancer formation and development. SOX10 was identified as a methylated gene in digestive cancers [20, 21]. It was also reported that SOX10 exhibits tumor suppressor activity by inducing tumor cell apoptosis, inhibiting invasion, and regulating cell epithelial to mesenchymal transition (EMT) in digestive cancers through suppressing Wnt/β-catenin signaling pathway [22]. Consistent with that, our results also indicated that SOX10 was significantly downregulated in gastric cancer, implying that the reduction of SOX10 expression could be a good predictor for gastric cancer.

The expression of FOXC1 has significance in the development, progression, and metastasis of gastric cancer, and overexpression of FOXC1 may serve as a useful marker for predicting the outcome of patients with gastric cancer [23]. Moreover, by comparative transcriptome analysis, Feng et al. found that FOXD1 was an important differentially expressed TF between metastatic gastric cancer and nonmetastatic gastric cancer [24]. Our results showed that FOXC1 and FOXD1 were upregulated in gastric cancer compared with normal tissues, which provides additional evidence for their roles of potential biomarkers.

It was reported that FOXL1 was also upregulated in pancreatic intraepithelial neoplasia [25]. Integration analysis of SNPs and gene expression profile revealed that FOXL1 regulated the most important DEGs of IRX1, SOX1, and MSX1 with risk associated SNP loci, which may serve as candidate biomarkers for diagnosis and prognosis of gastric cancer [26]. By the FOX family member such as FOXL1, hedgehog signals can induce WNT5A upregulation, which is a cancer-associated gene involved in invasion and metastasis of gastric cancer [27]. Another study reported that FOXL1 was the
| TFs | Log FC  | Count | Genes                                                                 |
|-----|---------|-------|----------------------------------------------------------------------|
| BRCA1 | 1.067827 | 49    | SLC6A6, NHLRC3, TAF2, POGK, GMFB, NUSAPI, TCF20, CXCL1, FANC, GCNT4, MPHOSPH9, TAF15, WRAP53, HNRNPAP2B1, API3, ATP1A3, COPA, TMEM132A, PGM2L1, CTR9, DXH37, SACP, ITSN1, SLC30A7, THUMPD2, ZNF707, CCDC34, HMGN1, SLC35A2, ENPP6, CHUK, PKRSCH, ARMCI0, RANBP1, LOC389906, CEP72, TIPIN, ILF3, GEMI5, DCLREIC, SPAG5, TRMT6, TTYH3, ZC3H11A, MIS18A, SUPV3L1, MND1, PTGES3 |
| ARID3A | 0.844259 | 47    | C9orf114, LRFN4, FTS3, LARP4, NFYA, PDRGI, ATP2A2, DPP6, ATP2C1, SNORD16-2, DCLREIB, NME1-NME2, CENPL, ZNF46, STIL, NLK, MFAP2, DPAGT1, SNRPN200, GDF15, ATP6, UHMK1, IFI30, TRMT1, MLH3, PLBD2, PARG, ITGA2, DARS2, LYE5, KIF4A, ADPKD, USP2, TRUB1, FGFR4, BRMSI, NEIL3, ZNF598, SAFB, NACPG2, C2orf15, MTHFD1 |
| EHF | 1.300121 | 42    | YWHAB, GCA, DTYMK, TAF4, STMNI, TOPMT, RBM2, RAD51D, DXX10, KIFCC, CCNE2, LOC50019304, SPTAN1, DNAJC14, NUP155, SUCV64H, SNX5, SST, AJUBA, ZBTB33, CCNB1, QSOX2, NEL, NOM1, OSBLP3, ILF3, UBE2T, UBE2C, SNRF5, CBFX, PKP4, EIF3J, GCLN1, BAZ1A, EXO1, ANKRD52, AGFG1, SNRPN40, TBLXRI, SPCEI, SGOL2 |
| SOX10 | −1.06478 | 42    | PTGES3, R3HDM1, TTYH3, RPRGRIPL, POM121, KIF2C2, GABBP1, SLC7A6, ZNF526, SYMPK, KLHL12, SETDB1, PK2, HNRNPC, POLD3, TRP, NOM1, THBS2, SULF1, SYN2, ATP3A, KIF20B, CHEKI, STIPI, LRPPRC, ZMYND15, LRRCSB, MAMDC2, TNFIRIP10B, SOX4, AURKAP5, NTS3A, TMEM199, CDK5RAP1, RAII4, SHQ1, DSCC1, ATP2A2, PTGRI, ZSCAN29, PMM2 |
| ZNF263 | 0.435573 | 41    | BCCRIP, CNOT6, CCT3, CKAP2L, ZNF335, XPOS, SMARCC1, BTG2, OLFM3, PSM2B, EFCAB11, WDHVV1, PALB2, NACPD2, TMEMS5, PDRG1, FHL1, SRP72, SOCS1, TEX21, TXNDC12, ATG7, DPAGT1, HIATL1, LAMB1, UBE20, TCOFI, NIT2, PLEKHG4, TNRC8, DUS4L, NLRC5, STAUI, TP53BP1, POLG, SSB, MMS22L, RAII4 |
|FOX1L1 | 0.69973 | 38    | WBPIII, SH3KBPI, USPI, TIMM8A, KRT18, LTV1, ZNF485, PK2, PODXI, ADHFEI, DIP2B, POLG2, PUS7, RCC2, DPM2, RPRGRIPL, BLOC1S2, WDRI2, NCEH1, IWSI, COG2, DEPC1, NCAH1, EPHB4, POLQ, CCT6A, MAPRE1, CENPW, SLC28A1, PIK3CB, RNF2, NSUN2, TYK2, DAZAPI, C2orf15, HN1L, SMYD5 |
| FEV | −0.75328 | 37    | FCHO1, ZDHHIC9, CCNF, PIK3CB, TOP3A, ZNF678, EML4, WDR43, FANCM, GPN1, COL4A1, MB21D1, Goras1P2, DUSPI2, LGALS8, WDR3, CD6, ZBTB41, EAFI, UFMR1, HSPPP2, PLAT1, COL1A1, ARFGAPI, IKBAP, NPMOL, KAT2B, TTI1, SPG21, FAM107A, RAD51, HMMR, UHMK1, BMP1, ZC3H3 |
| GATA3 | 0.606954 | 35    | VIT, PBK, AKAP8, ANAPC5, ILF2, NELN, RBM27, STX6, ZNF473, CHD4, MSHE, CREBZ6E, ZNF341, DBF4, ZNF507, PKP4, HNRNPD, CNOT6, U2SURP, CENPP, SRFPI, SUPV3L1, SMIFB1, CDKN3, NUP188, GCN1L1, NUPL1, MAMDC2, FMSI, RCD1, UBQLN4, SMARCA5 |
| FOXC1 | 1.20691 | 32    | MTPAP, BAZIA, CHEKI, SLC30A5, NCL, MAPRE1, AQP4, USPI4, EARS2, SYNCRIP, PALB2, SLC37A3, PHF6, POLR3E, TPM3, HOX9, CD46, CLCN5, GOLT1B, C2orf44, AAGAB, NEK2, FAM208B, MRYH9, UGQT1, NOL10, PRIMA1, ZNF92 |
first mesenchymal Modifier of Min and plays a key role in gastrointestinal tumorigenesis [28]. We found that FOXL1 was upregulated in gastric cancer compared with normal tissues, indicating that FOXL1 will be a powerful driver in the progression of gastric cancer.

The expression level of GATA3 was significantly increased in patients with gastric cancer [29]. Another study reported that GATA3 plays an important role in tumor progression of gastric adenocarcinoma, and the downregulation of GATA3 is associated with unfavorable prognosis in primary gastric adenocarcinoma [30]. Specifically, Keshari et al. found that the low GATA3 expression was associated with tumors with deeper invasion, higher lymph node metastatic status, cases with distant metastases, and a later TNM stage [30]. In our study, GATA3 was upregulated in gastric cancer compared with the normal tissues, which may be partly related to the TNM stage of patients with gastric cancer. Our results suggested that GATA3 plays vital roles in different developmental stages of gastric cancer. Further functional experiments are necessary to better understand the function of GATA3 in gastric cancer.

5. Conclusion

Taken together, our integrated analysis discovered a bunch of DEGs in gastric cancer. Moreover, the results of function enrichment analysis revealed that some biological functions or pathways may be closely related to the development of gastric cancer, including digestion, cell cycle, and homologous recombination. The constructed transcriptional regulatory network may be helpful to further understand the underlying regulatory mechanism of gastric cancer. Ten TFs regulating most downstream target genes were obtained: BRCA1, ARID3A, EHF, SOX10, ZNF263, FOXL1, FEV, GATA3, FOXC1, and FOXD1.

Abbreviations

DEGs: Differentially expressed genes
GEO: Gene Expression Omnibus
GO: Gene Ontology
KEGG: Kyoto Encyclopedia of Genes and Genomes
TFs: Transcription factors.

Competing Interests

The authors declare that they have no competing interests.

References

[1] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015.
[2] K. Aoyagi, K. Kouhjui, J. Kizaki, T. Isobe, K. Hashimoto, and K. Shirouzu, “Molecular targeting to treat gastric cancer,” World Journal of Gastroenterology, vol. 20, no. 38, pp. 13741–13755, 2014.
[3] T. Jian and Y. Chen, “Regulatory mechanisms of transcription factors and target genes on gastric cancer by bioinformatics method,” Hepato-Gastroenterology, vol. 62, no. 138, pp. 524–528, 2015.
[4] Y. Shi, J. Wang, Z. Xin, Z. Duan, G. Wang, and F. Li, “Transcription factors and microRNA-Co-regulated genes in gastric cancer invasion in ex vivo,” PLoS ONE, vol. 10, no. 4, Article ID e0122882, 2015.
[5] T. Barrett, S. E. Wilhite, P. Ledoux et al., “NCBI GEO: archive for functional genomics data sets—update,” Nucleic Acids Research, vol. 41, no. 1, pp. D991–D995, 2013.
[6] R. Gentleman, V. Carey, W. Huber et al., Bioinformatics and Computational Biology Solutions Using R and Bioconductor, Springer Science & Business Media, 2006.
[7] G. K. Smyth, “Linear models and empirical Bayes methods for assessing differential expression in microarray experiments,” Statistical Applications in Genetics and Molecular Biology, vol. 3, article 3, 2004.
[8] D. Tabas-Madrid, R. Nogales-Cadenas, and A. Pascual-Montano, “GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics,” Nucleic Acids Research, vol. 40, no. 1, pp. W478–W483, 2012.
[9] M. D. Young, M. J. Wakefield, G. K. Smyth, and A. Oshlack, “Gene ontology analysis for RNA-seq: accounting for selection bias,” Genome Biology, vol. 11, no. 2, article R14, 2010.
[10] M. Kanehisa and S. Goto, “KEGG: kyoto encyclopedia of genes and genomes,” Nucleic Acids Research, vol. 28, no. 1, pp. 27–30, 2000.
[11] E. Wingender, “The TRANSFAC project as an example of framework technology that supports the analysis of genomic regulation,” Briefings in Bioinformatics, vol. 9, no. 4, pp. 326–332, 2008.
[12] R. Knüppel, P. Dietze, W. Lehnb erg, K. Frech, and E. Wingender, “TRANSFAC retrieval program: a network model database of eukaryotic transcription regulating sequences and proteins,” Journal of Computational Biology, vol. 1, no. 3, pp. 191–198, 1994.
[13] M. E. Smoot, K. Ono, J. Ruscheinski, P.-L. Wang, and T. Ideker, “Cytoscape 2.8: new features for data integration and network visualization,” Bioinformatics, vol. 27, no. 3, pp. 431–432, 2011.
[14] K. Yamashita, S. Sakuramoto, M. Nemoto et al., “Trend in gastric cancer: 35 years of surgical experience in Japan,” World Journal of Gastroenterology, vol. 17, no. 29, pp. 3390–3397, 2011.
[15] J. H. J. Hoeijmakers, “DNA damage, aging, and cancer,” New England Journal of Medicine, vol. 361, no. 15, pp. 1475–1485, 2009.
[16] W. Chen, J. Wang, X. Li et al., “Prognostic significance of BRCA1 expression in gastric cancer,” Medical Oncology, vol. 30, no. 1, article 423, 2013.
[17] J. W. Kim, H. J. Cho, M. Kim et al., “Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer,” Cancer Chemotherapy and Pharmacology, vol. 71, no. 6, pp. 1435–1443, 2013.
[18] Z.-Z. Zhang, Y. J. C. Liu, X.-L. Yin, P. Zhan, Y. Gu, and X.-Z. Ni, “Loss of BRCA1 expression leads to worse survival in patients with gastric carcinoma,” World Journal of Gastroenterology, vol. 19, no. 12, pp. 1968–1974, 2013.
[19] M. Song, H. Kim, W. K. Y. Kim, S. P. I. Hong, C. Lee, and H. Kim, “High expression of AT-rich interactive domain 3A (ARID3A) is associated with good prognosis in colorectal carcinoma,” Annals of Surgical Oncology, vol. 21, supplement 4, pp. S481–S489, 2014.
CpG methylation profiling by reduced representation bisulfite sequencing,” *BMC Genomics*, vol. 14, article 11, 2013.

[21] J. Ying, H. Li, J. Yu et al., “WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/β-catenin signaling, and is frequently methylated in colorectal cancer,” *Clinical Cancer Research*, vol. 14, no. 1, pp. 55–61, 2008.

[22] X. Tong, L. Li, X. Li et al., “SOX10, a novel HMG-box-containing tumor suppressor, inhibits growth and metastasis of digestive cancers by suppressing the wnt/β-catenin pathway,” *Oncotarget*, vol. 5, no. 21, pp. 10571–10583, 2014.

[23] Y. Xu, Q.-S. Shao, H.-B. Yao, Y. Jin, Y.-Y. Ma, and L.-H. Jia, “Overexpression of FOXC1 correlates with poor prognosis in gastric cancer patients,” *Histopathology*, vol. 64, no. 7, pp. 963–970, 2014.

[24] D. Feng, X. Ye, Z. Zhu, Z. Wei, Q. Cai, and Y. Wang, “Comparative transcriptome analysis between metastatic and non-metastatic gastric cancer reveals potential biomarkers,” *Molecular medicine reports*, vol. 11, no. 1, pp. 386–392, 2015.

[25] N. B. Prasad, A. V. Biankin, N. Fukushima et al., “Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells,” *Cancer Research*, vol. 65, no. 5, pp. 1619–1626, 2005.

[26] T. Wang, Y. Xu, and P. Hou, “Identifying novel biomarkers of gastric cancer through integration analysis of single nucleotide polymorphisms and gene expression profile,” *International Journal of Biological Markers*, vol. 30, no. 3, pp. e321–e326, 2015.

[27] M. Katoh and M. Katoh, “Transcriptional mechanisms of WNT5A based on NF-κB, Hedgehog, TGFβ, and Notch signaling cascades,” *International Journal of Molecular Medicine*, vol. 23, no. 6, pp. 763–769, 2009.

[28] N. Perreault, S. D. Sackett, J. P. Katz, E. E. Furth, and K. H. Kaestner, “Foxl1 is a mesenchymal Modifier of Min in carcinogenesis of stomach and colon,” *Genes and Development*, vol. 19, no. 3, pp. 311–315, 2005.

[29] Q. Bie, P. Zhang, Z. Su et al., “Polarization of ILC2s in peripheral blood might contribute to immunosuppressive microenvironment in patients with gastric cancer,” *Journal of Immunology Research*, vol. 2014, Article ID 923135, 10 pages, 2014.

[30] R. P. Keshari, W. Wang, Y. Zhang et al., “Decreased expression of the GATA3 gene is associated with poor prognosis in primary gastric adenocarcinoma,” *PLoS ONE*, vol. 9, no. 2, Article ID e87195, 2014.

[31] M. D’Errico, E. de Rinaldis, M. F. Blasi et al., “Genome-wide expression profile of sporadic gastric cancers with microsatellite instability,” *European Journal of Cancer*, vol. 45, no. 3, pp. 461–469, 2009.

[32] Q. Wang, Y. G. Wen, D. P. Li et al., “Upregulated INHBA expression is associated with poor survival in gastric cancer,” *Medical Oncology*, vol. 29, no. 1, pp. 77–83, 2012.

[33] Z. Lei, I. B. Tan, K. Das et al., “Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil,” *Gastroenterology*, vol. 145, no. 3, pp. 554–565, 2013.

[34] R. A. Busuttil, J. George, R. W. Tothill et al., “A signature predicting poor prognosis in gastric and ovarian cancer represents a coordinated macrophage and stromal response,” *Clinical Cancer Research*, vol. 20, no. 10, pp. 2761–2772, 2014.

[35] Z. Qian, G. Zhu, L. Tang et al., “Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets,” *Genes Chromosomes and Cancer*, vol. 53, no. 11, pp. 883–894, 2014.